Shi-Ming Tu, MD

Full Member

Research Program:

Cancer Biology

Faculty Rank:

Professor

Campus:

University of Arkansas for Medical Sciences

College:

College of Medicine

Department:

Internal Medicine

Cancer Research Interest

Disease Site Focus: GU
Research Focus Area: Carcinogenesis
Type of Research: Translational
Research Keywords: cancer stem cells, germ cell tumor, prostate cancer
Research Interest Statement: My clinical research focuses on a stem-cell origin and nature of cancers as it pertains to intratumoral heterogeneity in germ cell tumors and the microenvironment in prostate cancer bone metastasis. I have developed laboratory protocols that enable us to evaluate the clinical features and biological characteristics of germ cell tumor with respect to its stem-like origins, lethal phenotypes, and somatic transformation. I have designed clinical trials that have established the feasibility and indicated the clinical efficacy of bone-targeted therapy and maintenance regimens for patients with prostate cancer. My other area of research interest concerns the origin and nature of variant GU tumors, such as atypical germ cell tumors and ductal prostate cancer.　These studies may help us elucidate a stem-cell origin and nature of cancers and explore improved therapeutic strategies for specific cancer subtypes and pertinent tumor phenotypes.

“S2200, A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2).” (NCT05411081)
“A031701 A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations” (NCT03609216)
“A feasibility Study Evaluating a Role for Maintenance therapy in Patients with Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy” (NCT06044025)
“S1802 “Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer.”” (NCT03678025)

Tu SM, Chen JZ, Singh SR, [et al.]. Stem Cell Theory of Cancer: Clinical Implications for Cellular Metabolism and Anti-Cancer Metabolomics. Cancers. 2024 16(3). PMID: 38339375. PMCID: PMC10854810.
Tu SM, Chen JZ, Singh SR, [et al.]. Stem Cell Theory of Cancer: Clinical Implications of Epigenomic versus Genomic Biomarkers in Cancer Care. Cancers. 2023 15(23). PMID: 38067237. PMCID: PMC10705798.
Tu SM, Aydin AM, Maraboyina S, [et al.]. Stem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy. Cancers. 2023 15(22). PMID: 38001645. PMCID: PMC10670143.
Tu SM, Aydin AM, Maraboyina S, [et al.]. Stem Cell Origin of Cancer: Implications of Oncogenesis Recapitulating Embryogenesis in Cancer Care. Cancers. 2023 15(9). PMID: 37173982. PMCID: PMC10177345.
Tu SM, Singh SR, Arnaoutakis K, [et al.]. Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench. Cancers. 2022 14(14). PMID: 35884406. PMCID: PMC9321703.
Tu SM, Moran C, Norton W, Zacharias NM. Stem Cell Theory of Cancer: Origin of Metastasis and Sub-clonality. Seminars in diagnostic pathology. 2022. PMID: 35729019.
Tu SM, Guo CC, Chow DS, Zacharias NM. Stem Cell Theory of Cancer: Implications for Drug Resistance and Chemosensitivity in Cancer Care. Cancers. 2022 14(6). PMID: 35326699. PMCID: PMC8946169.
Tu SM, Pisters LL. Stem-Cell Theory of Cancer: Implications for Antiaging and Anticancer Strategies. Cancers. 2022 14(5). PMID: 35267646. PMCID: PMC8909197.